Pulmonary embolism
Conditions
Interventions
Control group:Anticoagulant therapy, heparinoids given immediately after diagnosis is confirmed, unfractionated heparin pumped continuously, and APTT monitored to maintain for 50 to 70 seconds
or low molecular weight heparin according to the anticoagulation regimen of 0.1ml/10kg, sc, every 12 hours, 48 hours at the discretion of the clinician.
Intervention group:Interventional thrombectomy, interventional thrombectomy is given within 48 hours after the start of anticoagulation therapy, and an 8F thrombectomy catheter is placed with the assi
Sponsors
Beijing Chao-Yang Hospital, Capital Medical University
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1. Meet the diagnostic criteria for intermediate- and high-risk PTE. CTPA showed a right ventricular end-diastolic diameter/left ventricular end-diastolic diameter of > 0.9. Elevated cardiac biomarkers, including BNP, NT-pro BNP, troponin. 2. CTPA showed that the thrombus was located in the lobar artery and above. 3. Age: 18 years old or older. 4. Voluntarily participate in this study and sign the informed consent form.
Exclusion criteria
Exclusion criteria: 1. Chronic pulmonary embolism or acute pulmonary embolism on the basis of chronic pulmonary embolism judged by clinicians (such as cardiac color ultrasound estimated sPAP>=70 mmHg). 2. Those who are allergic to contrast medium and cannot undergo iodine contrast agent examination and interventional treatment. 3. Patients with chronic kidney disease or renal insufficiency (creatinine clearance rate < 30 ml/min) who cannot tolerate contrast examination. 4. Patients with left heart cardiovascular disease, such as left bundle branch block, etc., who cannot tolerate interventional therapy. 5. Those with high risk of interventional operation after pacemaker placement within 1 month. 6. Uncontrolled hyperthyroidism is not suitable for contrast examination. 7. Pregnant women. 8. Those with other serious diseases and the expected survival time is less than 3 months. 9. Those who do not agree to enter the clinical research room.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| RV/LV change ratio; | — |
Countries
China
Contacts
Public ContactLi Jifeng
Beijing Chao-Yang Hospital, Capital Medical University
Outcome results
None listed